Physician profile
Michael S Jacobson
NPI 1376546549
$40,210.92
in general payments reported to CMS, 2019-2025
21 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,558 · 2020: $3,676 · 2021: $14K · 2022: $13K · 2023: $2,138 · 2024: $1,181 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $28,867.78 | 2019-2022 | |
| Alimera Sciences, INC. | $2,526.34 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $1,612.61 | 2019-2024 | Vabysmo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $1,451.09 | 2019-2025 | Eylea, Eylea Hd |
| Allergan, INC. | $776.66 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $731.92 | 2022-2025 | Syfovre |
| Notal Vision, INC. | $665.11 | 2022 | |
| Astellas Pharma US INC | $660.88 | 2023-2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $607.32 | 2019-2022 | |
| Alcon Vision LLC | $515.31 | 2020-2021 | |
| Abbvie INC. | $487.87 | 2022-2024 | |
| Carl Zeiss Meditec USA, INC. | $381.31 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $312.48 | 2024 | Xipere, Visudyne |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $135.51 | 2019-2021 | |
| Dutch Ophthalmic, USA | $126.78 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $123.27 | 2022 | |
| Eyepoint US, INC. | $79.06 | 2019-2024 | |
| Coherus Oncology, INC. | $64.28 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $41.69 | 2019 | |
| Halozyme INC | $24.74 | 2024 | Hylenex Recombinant |
| Sun Pharmaceutical Industries INC. | $18.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$441,366.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.